Google+

Biotech Companies

 

Adecto-cropped
 

 

 

 

 

 

ADEPTRIXC81a- Rev. png

 

 

 

 

 

 

 

 

 

 

Cell Assay Innovations

 

 

 

 

 

Genomic Expression.png

 

 

 

 

 

Epathochhem Logo 1.2

 

 

 

 

 

ihope-logo

 

 

 

 

 

InsomniSolv-Logo_FinalColor

 

 

 

 

 

IVIVA Medical, Inc.

 

 

lariat_final
 

 

 

MiMecore
 

 
 

 
OWLife
 

 
 

 

 

 

 

 

 

 

 

 

 

Seqwell logo. jpg

 

 

 

TBS_logoDesign_05_CMYK

 

 

 

 

TrBio_Color

 

 

 

 

 

 

 

Virtech Bio graphic

 

Adecto Pharmaceuticals  www.adectopharma.com

Adecto Pharmaceuticals identified a critical driver of tumor growth and metastasis and is developing antibody-based therapeutics against triple-negative breast cancer and other aggressive malignancies.

Gail Sonenshein, President; Nora Mineva, CSO

 


Adeptrix  
www.adeptrix.com

Developing the next generation of bead-based bioassays, which employ mass spectrometry and optical imaging to facilitate high information content proteomic research.

Vladislav Bergo, CEO  

 

 

Cellanyx Diagnostics LLC  www.cellanyx.com

Developing in vitro tissue and cell culturing techniques for use in research and in vitro diagnostics, specifically prognostic information for prostate cancer treatment decisions.

Ashok Chander,CEO; Mani Foroohar,CSO

 

Cell Assay Innovations, Inc.   www.cellassayinnov.com

A biotechnology service company dedicated to cell-based assay technology development with a focus on proprietary kinase assay panels for drug screening and other cell culture services.

Deborah Moshinsky, President; LiPing Wu, CSO

 

Genomic Expression   www.genomicexpression.com

Offers a proprietary OneRNA™ technology platform that dramatically simplifies quantitative RNA-sequencing, using proprietary algorithms and databases, assisting the clinical development of new cancer drugs with a focus on immune therapies.

Gitte Pederson, CEO; Tanya Kanigan, CTO

 

HepatoChem   www.hepatochem.com

Offers pharmaceutical and biotech companies reliable and efficient access to small molecule metabolites in order to accelerate drug R&D and reduce costs.

Marc Bazin, President; Ryan Buzdygon, Director of Operations

 

iHope Network www.ihopenetwork.com

iHope Network (IHN) uses its network of certified licensed clinicians to deliver technology-guided Cognitive Behavioral Therapy (CBT) treatment via phone and video conferencing.

Tom Hunter, CEO; Paul Earl, COO

 

InSomniSolv  www.angel.co/insomnisolv 

Developing  a neurostimulator device to mitigate insomnia.

Peter Kelley, Founder; John Douglas, Consultant

 

IVIVA Medical, Inc. (website under construction)

Developing bioengineered autologous dialysis grafts, an “implantable artificial kidney,” to substitute for, augment, or replace human kidney function without hemodialysis or the need for immunosuppression.

Harald Ott, MD, President & CEO; Charles Klassen, Research Scientist

 

Lariat Biosciences (website under construction)

Developing a non‐invasive diagnostic to detect early signs of cancer based on circulating DNA fragments arising from the death of tumor cells which carry the mutant genetic signature that gave rise to the abnormal growth.

Jonathan Larson, CEO

 

MiMecore Therapeutics LLC www.mimecore.com

Developing a novel suite of engineered proteoglycan-mimics designed to assist in the healing and restoration of soft tissue extracellular matrix compromised by age, injury or medical disorder.

Vince Novak, CEO & Founder; Tom Jozefiak, VP Science & Technology

 

OWLife Technologies (website under construction)
Developed a virtual reality platform designed to empower people diagnosed with diabetes to better manage their disease and their lives. This approach offers a peer community and individualized simulation (avatar) experiences coupled with shared telemedicine group visits led by medical experts.

Suzanne Mitchell, MD, CEO
 

 

RAN Biotechnologies, Inc.   www.ranbiotechnologies.com

Designs and manufacture two types of materials: (1) Solid Resins for selective capture and controlled release of viruses, bacteria, and proteins. Examples of related applications are viral clearance, vaccine purification, fluid disinfection and diagnostics; (2) FluoroSurfactants for droplet microfluidics.

Roger Nassar, CEO

 

seqWell, Inc. www.seqwell.com

Offers a DNA sequencing service called kiloSEQ ™, based on novel and proprietary technology that will enable high-quality, long-read sequencing of plasmids and amplicons for development of therapeutic biologicals and synthetic biology applications.

Joseph Mellor, CEO; Jack Leonard, Head of Operations

 

Thrive Bioscience, Inc. www.thrivebio.com

Is developing Smart Incubation Systems™ that will automatically monitor, maintain, passage, and assay cell and tissue culture.

Alan Blanchard, CSO; Thomas Farb, COO/CFO; Brian Foley, VP of Engineering & Manufacturing

 

Tribiotica  www.tribiotica.com

TriBiotica’s proprietary technology uses the tumor’s unique genetic signature to force the tumor cells to assemble novel immune targets that would not be naturally produced, but which allows specific elimination of tumor cells

Jim Kurnick, MD, Chairman; Matt Lawlor, President; Ian Dunn, CTO; Estelle Newton

 

VirTech Bio (website under construction)

Develops innovative therapies for organ and tissue preservation, ex-vivo organ management and biomarker discovery using a technology platform combining machine perfusion with a new hemoglobin-based oxygen carrier solution.

Joseph Tucker, President; W.R. Light, VP R&D